IL6 and atrial fibrillation: Similarly, the direct suppression of IL-1β with specific monoclonal antibody canakinumab results in the downstream suppression of IL-6 and TNF-α, limiting atrial remodelling and making it an excellent potential therapy to reduce AF burden.